Heavy menstrual bleeding has a significant impact on women's lives. Approximately 25% of female consultations in general practice surround this area and heavy menstrual bleeding has a significant impact on quality of life. Women tend not to seek advice from GPs because they feel like it is something that is an accepted part of life and they continue suffering with it. It is well established that those who think that it is just a normal part of life may have significant heavy bleeding. In simple terms, you can assess how bad the impact is on their lives by asking questions about their social history, impact upon work and family, if they're getting tired, using a lot of sanitary wear, soiling their underwear or bed sheets or mattresses. It is an easy assessment as there is a disease-specific quality of life instrument that has been used in studies as a simple way of assessing that. Heavy menstrual bleeding is something that can be treated easily, as there are now very good treatments available from GPs to improve quality of life. So women should be encouraged to seek help. There is good evidence that there are several medicines available. These are dependent on age and the type of problems. It is better to use the combined oral contraceptive pill the younger you are, but as you get older (over 35-37 years), progestogens, such as Medroxyprogesterone Acetate (Depo-Provera ® [Pharmacia] injections, or high-dose oral progestogens, such as norethisterone, are preferred on a long-term basis. The most recent evidence has shown that the Mirena coil (Bayer, UK) is actually the most effective first-line treatment. Nonhormone treatments that have also been shown to be effective are tranexamic acid and mefenamic acid. Tranexamic acid can be used at any age and it is particularly good for those who are trying to get pregnant as it is not a contraceptive. Tranexamic acid effects are dose-dependent. You should start off with 500 mg three times a day and then increase to 1 g three times a day, up to a maximum dose of 1.5 g three Janesh Gupta speaks to Caroline Telfer, Commissioning Editor I qualified from University of Leeds, UK in 1987. When I was a 4th year medical student I decided to pursue Obstetrics and Gynecology (O&G) as a career because it involved dealing with women who are going through a happy time in their life, having babies which is a physiological part of life. O&G is a fast-acting specialty which is a combination of medicine and surgery, which led me into this career. After Leeds, I went to Dundee, Scotland as a Senior Registrar, then moving to Birmingham, UK in 1998 as a Senior Lecturer and then getting my Chair as Professor of Obstetrics and Gynecology in 2006.
Womens Health (2014) 10(5) future science group Interview Gupta times a day. Starting at higher doses can cause stomach cramps. Most women respond to 500 mg-1 g doses. Medication should be started at the start of menses until the end of your menses and it should reduce menstrual blood loss by 50% on average, but it is also dependent on patient compliance.
Q Bayer HealthCare recently issued results from market research of 250 GPs that explores awareness of the NICE guidelines on treating heavy menstrual bleeding. Why was this study necessary?
I think that most types of evidence-based guidelines tend to be very slow in implementation into the wider clinical scenario, so I think it is important to assess the impact of guidelines at the level of patient care. So this market research was good to assess whether NICE guidelines on heavy menstrual bleeding, published in 2007, were actually implemented and it shows that awareness could be a lot better. These particular guidelines are going to be updated in 2014-2015, and I think it's important to continually check that the guidelines are being implemented into practice.
Q Can you explain a little more about the design of the study?
The sample was 250 GPs from throughout the UK, but with the highest prevalence in the London area. It was just a question based on what treatments were prescribed when a patient presents with heavy menstrual bleeding. For example, examine and investigate (e.g., full blood count) what type of treatments were used. It was a well-designed questionnaire to check whether evidence-based practice was being followed.
Q What were the results of the study?
The study showed that for women who are suitable for either hormonal or non-hormonal intervention, where the recommended treatment is the Mirena coil, eight out of 10 GPs were unaware of this recommendation. This is quite a concern because the 2007 NICE guidelines say that Mirena coil should be 'considered' as the first-line treatment. They also found that only 3% of GPs routinely recommended Mirena coil as a first-line treatment. Having said that, the most frequent first-line treatment was tranexamic acid, which is the other guideline recommendation, which we also know does work. The Mirena coil needs a fitting, which is not always available in general practice, so GPs may need referral to another GP practice or hospital. So that may be the downside of this treatment.
Q How do you think these results will affect the treatment going forward?
I think it should say that the big difference between tranexamic acid and the Mirena coil is that the coil does not suffer from compliance issues. After fitting the Mirena coil you do not have to do anything for 5 years. Tranexamic acid has a potential compliance issue as it must be taken every month. I think despite that, it is about the motivation and explanation that the GP provides that will alter compliance issues. As I said, the Mirena coil is easy to 'fit and forget', but it does need the intervention of fitting, which is not always available in every GP practice, whereas tranexamic acid is easy to prescribe, but it may be that the efficacy is watered down due to compliance issues.
Q How do you think the study will translate into the clinic?
The study should make GPs more aware that Mirena coil is a good first-line treatment in those who do not want pregnancy. For those who wish to continue with fertility then tranexamic acid is the next best option. The guidelines will change to say that this should definitively be used as a first-line treatment because of the new study published by myself in the New England Journal of Medicine on the results of the ECLIPSE trial. That will have a major bearing internationally as well. I think that women should not be shy in presenting with problems, such as heavy menstrual bleeding, that they think should be tolerated. There are effective treatments out there, if help is sought. In the past, we did not have the evidence supporting the treatments but now we do, particularly for heavy menstrual bleeding. I think that is going to be the main issue; getting women to be aware and to seek help. I think that treatments for benign gynecology are hugely advancing. I think the most important advances will be treatments that do not involve major surgery. Currently we do, for example, hysterectomies but pharmaceutical interventions will probably lead to more preventative and effective treatments. If surgery is required then lesser invasive methods, such as endometrial ablation, will be done, which will lead to faster recovery. In another example, there is a condition called endometrial hyperplasia, which is a pre-malignant state, that if left untreated can become endometrial cancer over many years. We have new data that shows that the Mirena coil can help avoid surgery in approximately 80% of patients. So there are many ways of treating patients without them having to undergo a hysterectomy.
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